drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Patient-derived T cells engineered to express a CAR targeting BCMA (TNFRSF17) on plasma cells; CAR signaling activates T cells to proliferate and kill BCMA-expressing multiple myeloma cells via cytotoxic mechanisms.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor targeting BCMA (TNFRSF17) on plasma cells. BCMA engagement triggers CAR CD3zeta and co-stimulatory signaling, leading to T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of BCMA-expressing multiple myeloma cells via HLA-independent recognition.
drug_name
BCMA (TNFRSF17)-directed autologous CAR-T cells
nct_id_drug_ref
NCT06647329